Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial.

ABSTRACT:

Background

Past clinical trials of docosahexaenoic Acid (DHA) supplements for the prevention of Alzheimer's disease (AD) dementia have used lower doses and have been largely negative. We hypothesized that larger doses of DHA are needed for adequate brain bioavailability and that APOE4 is associated with reduced delivery of DHA and eicosapentaenoic acid (EPA) to the brain before the onset of cognitive impairment.

Methods

33 individuals were provided with a vitamin B complex (1 mg vitamin B12, 100 mg of vitamin B6 and 800 mcg of folic acid per day) and randomized to 2,152 mg of DHA per day or placebo over 6 months. 26 individuals completed both lumbar punctures and MRIs, and 29 completed cognitive assessments at baseline and 6 months. The primary outcome was the change in CSF

SUBMITTER: Arellanes IC 

PROVIDER: S-EPMC7502665 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature